US-based diagnostic information services provider Quest Diagnostics Quest has closed the previously announced acquisition of its joint venture partners’ interests in Mid America Clinical Laboratories (MACL).
Quest now wholly owns MACL’s laboratory in Indianapolis and approximately 50 patient service centres across Indiana.
Following the acquisition, the company now offers professional lab management services for approximately 30 hospitals in Indiana.
The hospitals are owned and managed by Community Health Network and Ascension St Vincent, the former joint venture partners in MACL.
Additionally, the company’s speciality pathology business AmeriPath will continue to offer a range of innovative clinical laboratory and pathology services to these hospitals and across Indiana.
Separately, Quest Diagnostics has launched an automated next-generation sequencing (NGS) engine to enhance AncestryHealth.
AncestryHealth, consumer genetics offering launched by genomic family history company Ancestry, offers genetic screening for a number of health conditions, including heart disease, breast cancer, colon cancer and blood disorders.
Quest’s NGS technology helps AncestryHealth to offer ‘highly accurate and valuable’ genetic health screening information compared to tests based on microarray technology.
Quest Diagnostics CEO and president Steve Rusckowski said: “This improvement in automating next-generation sequencing will enable genetic screening faster and at a much lower cost, and could have profound implications for healthcare in the future, truly empowering better health through actionable insights for millions of people who want to know more about their health risks.”
Quest is offering the technology for use in AncestryHealth and AncestryDNA offerings under an exclusive agreement. Additional details of the agreement were not disclosed.
In a separate development, US-based medical device company Ra Medical Systems closed its previously announced public offering of a total of 34,285,714 shares of common stock.
The gross proceeds of the offering were approximately $12m with each share priced at $0.35.
The company plans to use the proceeds from the offering for general corporate purposes and to support its engineering efforts and atherectomy indication trial.